Retrospective study of patients with metastatic melanoma to describe the utility of monitoring neutrophil and C‐reactive protein (CRP) levels in the evaluation of pyrexia during combination therapy with dabrafenib and trametinib
Latest Information Update: 14 Nov 2019
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 14 Nov 2019 New trial record